According to TipRanks.com, Kim is a 5-star analyst with an average return of 43.6% and a 72.1% success rate. Kim covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Aurinia Pharmaceuticals, and Aldeyra Therapeutics.
Pharvaris has an analyst consensus of Moderate Buy, with a price target consensus of $49.00, a 27.5% upside from current levels. In a report released today, Leerink Partners also initiated coverage with a Buy rating on the stock with a $50.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.